Application of echinatin to preparation of medicines for resisting esophagus cancer

A technology of licorice chalcone and esophageal cancer, applied in the field of medicine, can solve problems such as side effects and failure to achieve expected effects, and achieve the effects of inhibiting growth, inhibiting tumor formation, and increasing sensitivity

Active Publication Date: 2020-05-29
JINAN UNIVERSITY
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinical experience shows that this treatment method often fails

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of echinatin to preparation of medicines for resisting esophagus cancer
  • Application of echinatin to preparation of medicines for resisting esophagus cancer
  • Application of echinatin to preparation of medicines for resisting esophagus cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Embodiment 1 single drug experiment

[0050] CCK-8 experiment: Take KYSE30 and KYSE270 cells in good growth state, digest and count to adjust the cell density, and inoculate in a 96-well plate according to the number of 50 μL / 1000 cells. After the cells adhered to the wall overnight, the 50 mM licorice chalcone stock solution was diluted with DMEM medium to a certain concentration gradient, and 50 μL was added to each well. Four cell treatment groups were set up, the concentrations of licorice chalcone were 0 μM, 10 μM, 20 μM and 40 μM, respectively, and each group had 3 duplicate wells, and a blank well was set. At 0, 24, 48, 72, 96, and 120 hours, add 10 μL of CCK-8 to each well according to the instructions of the CCK-8 kit (avoid light during the addition, try to avoid the difference between the duplicate wells and avoid the generation of air bubbles) at 37°C , 5%CO 2 After incubating in the incubator for 2 h, use a multifunctional microplate reader to read the ab...

Embodiment 2

[0056] Embodiment 2 combined administration experiment

[0057] CCK-8 experiment: Take KYSE30 and KYSE270 cells in good growth state, digest and count to adjust the cell density, and inoculate in a 96-well plate according to the number of 50 μL / 1000 cells. After the cells adhered to the wall overnight, the 50mM licorice chalcone stock solution was diluted with DMEM medium to a certain concentration gradient, while the 100mM 5-fluorouracil stock solution was diluted with DMEM medium to a certain concentration gradient, and 50 μL of working solution was added to each well. Four cell treatment groups were set up, control group (DMSO), 5-fluorouracil group (concentration in KYSE30 was 1.25 μmol / L, concentration in KYSE270 was 0.3 μmol / L), licorice chalcone group (Echinatin=20 μmol / L) 1. Combination group (Echinatin+5-FU=20 μmol / L+1.25 μmol / L in KYSE30 and Echinatin+5-FU=20 μmol / L+0.3 μmol / L in KYSE270), each group has 3 replicate wells. At 0, 24, 48, 72, 96, and 120 hours, add 10...

Embodiment 3

[0061] Embodiment 3 in vivo experiments

[0062] Construction of subcutaneous model and treatment of nude mice with different drug concentrations

[0063] Select 18 female nude mice (balb / c-nu / nu) aged 6-8 weeks, set up 6 mice in the control group and 12 mice in the experimental group, and construct the tumor subcutaneous tumor model.

[0064] (1) Subcutaneously inject 5×10 per nude mouse 6 For the number of esophageal cancer cells KYSE270, resuspend the cells in 100 μL Matrigel mixture (PBS:Matrigel=volume ratio 1:1, the pH of PBS (1×) is 7.2±0.1)

[0065] (2) Anesthetize the nude mice before the experiment, evaluate the degree of anesthesia through painless and painful stimulation, and determine that the nude mice are under anesthesia;

[0066] (3) The resuspended cells were subcutaneously injected into 18 nude mice with a microinjector with a 25G needle.

[0067] Licochalcone treatment: Nude mice were subcutaneously injected with KYSE270 cells for a week, and when the tu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of echinatin to preparation of medicines for resisting esophagus cancer, and belongs to the technical field of medicine and pharmacy. For the first time, the inventor of the invention finds that echinatin in vitro level has restraining effects on cell proliferation, transfer and invasion of the esophagus cancer, and the echinatin can effectively restrain thegrowth of the esophagus cancer in vivo. In addition, the inventor of the invention also finds that when the echinatin and 5-fluorouracil are in united medication, the echinatin can increase the sensibility of esophagus cancer cells to the 5-fluorouracil. Besides, blood biochemistry conventional detection of tested animals proves that the echinatin can restrain the growth of the esophagus cancer, and besides, does not have obvious side effects. A new medication selection is provided for treatment of the esophagus cancer.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of licorice chalcone in the preparation of anti-esophageal cancer drugs. Background technique [0002] Esophageal cancer is a relatively common digestive tract tumor with high morbidity and mortality. Currently, the treatment of choice for esophageal cancer is complete surgical resection of the lesion and regional lymph nodes. However, since the disease has no obvious abnormal symptoms in the early stage, when the patient is diagnosed, most of them have developed to the middle and late stage. At this time, radical surgical treatment for the patient will not only fail to achieve the ideal therapeutic effect, but will seriously traumatize the patient's body. . For such patients, concurrent chemotherapy is used clinically, and the commonly used chemotherapy drugs are cisplatin and docetaxel. However, clinical experience shows that this treatment metho...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/122A61P35/00A61P35/04A61K31/513
CPCA61K31/122A61P35/00A61P35/04A61K31/513A61K2300/00
Inventor 许雯雯李斌刘琴文洪盼
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap